IPL for sun spots: confirm the spot before comparing the device

IPL can be a reasonable subject for a consultation about a confirmed benign solar lentigo, commonly called a sun spot. An FDA clearance for a named IPL device and filter may include lentigines, but it does not establish that every dark mark is a lentigo or that every IPL machine is cleared for that use. First identify the lesion; then compare the exact device, intended endpoint and pigment-risk plan.¹²

The phrase “sun spots” is convenient in a search box and imprecise in a treatment plan. It can refer to a benign lentigo, a freckle, a post-inflammatory mark, melasma or something that needs medical evaluation. IPL is a technology category, not a diagnosis. A consultation that starts with a package count before anyone identifies the mark has the order of decisions backward.

The diagnosis gate is the most valuable step

The American Academy of Dermatology advises having a dermatologist examine a presumed age spot before treating it. Other marks can include seborrheic keratoses, actinic keratoses and skin cancer. Cosmetic fading could obscure an important lesion and delay a diagnosis.¹

That does not mean every brown mark is dangerous. It means a light-based service should not make the diagnosis by assuming a spot’s color or location proves sun damage. If the mark is changing, atypical, raised, symptomatic or simply uncertain, the useful next appointment is an examination rather than an IPL package.

The melasma guide addresses a condition that may also look brown in photographs but has a different pattern and management question. A pigmented-lesion clearance should not be used as a blanket “IPL treats all brown spots” claim.

Read the 510(k) as a device record

In January 2026, FDA issued a 510(k) clearance for the Vydence Family of Lasers. The summary lists lentigines among benign pigmented lesions for specified IPL filter configurations. That is an example of a real product-and-filter claim; it is clearance, not drug approval and not evidence that every salon or practice owns the same configuration.²

The summary contains multiple filters and other laser components with different lists of intended uses. If a clinic cites this record, ask which exact platform, handpiece and filter it uses and which line of the clearance matches the proposed procedure. A screenshot of another company’s FDA record is not proof of a particular practice’s device identity or staff training.

The FDA record also cannot decide whether a patient’s mark is benign. Its listed use presupposes the right target. It does not establish an individual response rate, the number of sessions to buy, or a guarantee of uniform skin tone. Those are clinical and commercial claims requiring their own evidence and plan.

Compare an IPL plan with other ways to address the same mark

AAD describes topical products and procedures such as lasers, peels and freezing among possible approaches for age spots. Procedures can act faster than a topical course but can also cost more and have a higher side-effect burden. That is a general comparison, not a claim that one specific IPL protocol is superior.¹

IPL uses broad-spectrum light filtered for a particular target and device design. A laser uses a different light delivery. A chemical peel addresses skin through a chemical injury. None should be chosen simply because a consultation photo shows brown pigment. The provider should explain why the selected tool matches the diagnosed lesion and the person’s skin context.

If the stated goal is “remove every spot,” ask how the practice will handle marks it cannot identify confidently, and what happens when the diagnosis changes. A sound plan may separate lesions that belong in a medical skin exam from cosmetic marks that can be discussed for treatment.

Make the estimate comparable

An IPL quote needs a defined treatment area, named device, number of proposed visits, what the package includes, and who evaluates a mark that does not behave as expected. A single-spot plan and a full-face photofacial are not the same unit of service. Nor is an “IPL” quote necessarily comparable with a laser or peel quote if each assumes a different diagnosis.

Ask for the total proposed price and what is included in assessment and follow-up. Avoid treating an advertised “spots erased” photo as a measured outcome for your skin. Lighting, tanning, makeup, image processing and follow-up time can all change how such a photograph appears.

South Florida’s strong year-round sun exposure makes the timing and sun-protection discussion practical, but it does not make a Florida-only medical rule. The clinician should explain how recent tanning and future exposure affect the proposed plan and how it will assess pigment change after treatment. The goal is a documented plan for the specific mark, not a seasonal slogan.

Bring three questions to the provider

1. What is this spot, and who made that assessment? If uncertain, who examines it before a cosmetic procedure?
2. Which exact IPL device and filter will be used, and where does its FDA summary list the intended benign-lesion use?
3. What endpoint, risks, alternatives, visit count and total quote are being proposed for this diagnosed lesion?

The IPL provider hub can help locate relevant local practices. Use those questions to compare consultations. A credible answer begins with the spot’s identity and ends with a product-specific plan you can understand.